The promotion and marketing of oxycontin: Commercial triumph, public health tragedy

A. Van Zee

American Journal of Public Health, 2009, vol. 99, issue 2, 221-227

Abstract: I focus on issues surrounding the promotion and marketing of controlled drugs and their regulatory oversight. Compared with noncontrolled drugs, controlled drugs, with their potential for abuse and diversion, pose different public health risks when they are overpromoted and highly prescribed. An in-depth analysis of the promotion and marketing of OxyContin illustrates some of the associated issues. Modifications of the promotion andmarketing of controlled drugs by the pharmaceutical industry and an enhanced capacity of the Food and Drug Administration to regulate and monitor such promotion can have a positive impact on the public health.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (56)

Downloads: (external link)
http://hdl.handle.net/10.2105/AJPH.2007.131714

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:aph:ajpbhl:10.2105/ajph.2007.131714_4

DOI: 10.2105/AJPH.2007.131714

Access Statistics for this article

American Journal of Public Health is currently edited by Alfredo Morabia

More articles in American Journal of Public Health from American Public Health Association
Bibliographic data for series maintained by Christopher F Baum ().